Table 1 Baseline characteristics of patients with UC treated with ADA or IFX
Adalimumab (ADA) (n=111) | Infliximab (IFX) (n=282) | P-value | |
|---|---|---|---|
Age (y) | 42.95 ±14.09 | 41.43 ±13.40 | 0.3191 |
Age at diagnosis (y) | 34.42 ±13.72 | 32.68 ±12.74 | 0.2352 |
BMI (kg/m2) | 25.23 ±4.11 | 25.14 ±5.17 | 0.8771 |
Female gender | 75 (67.57) | 167 (59.22) | 0.1256 |
Caucasian | 61 (54.95) | 198 (70.21) | 0.0025 |
Active smoking | 6 (5.61) | 28 (10.11) | <0.001 |
Presence of comorbidities | 43 (38.74) | 110 (39.29) | 0.9204 |
Disease extension | |||
Pancolitis | 71 (64.55) | 173 (61.57) | 0.8599 |
Left sided colitis | 33 (30.00) | 91 (32.38) | |
Distal colitis | 6 (5.45) | 17 (6.05) | |
Extraintestinal manifestations (EIM) | 46 (42.59) | 91 (32.50) | <0.001 |
Rheumatological | 31 (28.70) | 60 (21.43) | 0.002 |
Dermatological | 7 (6.48) | 14 (5.00) | 0.127 |
Hepatic | 7 (6.48) | 9 (3.21) | 0.617 |
Ocular | 0 | 3 (1.07) | 0.5633 |
Thromboembolic events | 3 (2.78) | 8 (2.86) | 0.132 |
Corticosteroids at baseline | 68 (61.82) | 209 (74.64) | <0.001 |
Concomitant azathioprine | 65 (58.56) | 234 (82.98) | <0.0001 |
Time between diagnosis and onset of anti-TNF (y) | 6.33 ±5.65 | 5.73 ±5.39 | 0.240 |
Previous use of biological therapy | 36 (32.43) | 40 (14.23) | 0.643 |
Clinical disease activity | |||
Remission | 2 (1.94) | 6 (2.21) | 0.2853 |
Mild | 18 (17.48) | 28 (10.33) | |
Moderate | 65 (63.11) | 179 (66.05) | |
Severe | 18 (17.48) | 58 (21.40) | |
Mayo endoscopic subscore | |||
0 - remission | 3 (2.91) | - | 0.002 |
1 - mild | 7 (6.79) | 8 (2.94) | |
2 - moderate | 27 (26.20) | 109 (40.07) | |
3 - severe | 66 (64.08) | 155 (56.98) | |